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A B S T R A C T
Purpose: We analyzed the long-term postoperative outcome and possible predictive factors of the
outcome in surgically treated patients with refractory extratemporal epilepsy.
Methods: We retrospectively analyzed 73 patients who had undergone resective surgery at the Epilepsy
Center Brno between 1995 and 2010 and who had reached at least 1 year outcome after the surgery. The
average age at surgery was 28.3  11.4 years. Magnetic resonance imaging (MRI) did not reveal any lesion in
24 patients (32.9%). Surgical outcome was assessed annually using Engel’s modiﬁed classiﬁcation until
5 years after surgery and at the latest follow-up visit.
Results: Following the surgery, Engel Class I outcome was found in 52.1% of patients after 1 year, in 55.0%
after 5 years, and in 50.7% at the last follow-up visit (average 6.15  3.84 years). Of the patients who
reached the 5-year follow-up visit (average of the last follow-up 9.23 years), 37.5% were classiﬁed as Engel IA
at each follow-up visit. Tumorous etiology and lesions seen in preoperative MRI were associated with
signiﬁcantly better outcome (p = 0.035; p < 0.01). Postoperatively, 9.6% patients had permanent neurological
deﬁcits.
Conclusion: Surgical treatment of refractory extratemporal epilepsy is an effective procedure. The
presence of a visible MRI-detected lesion and tumorous etiology is associated with signiﬁcantly better
outcome than the absence of MRI-detected lesion or other etiology.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
More than 30 percent of patients with epilepsy are refractory to
antiepileptic drug treatment.1 Partly because of this relatively high
number, epilepsy surgery is an intrinsic part of the algorithm of
epilepsy treatment.
The short- or long-term efﬁcacy of various types of resections
for epilepsy in different anatomical locations has been widely
studied.2–5 However, there have been only two ‘‘Class I’’ studies
evaluating the effect of surgical treatment of epilepsy. Both of them
were conducted in patients with refractory temporal lobe epilepsy* Corresponding author. Tel.: +420 532 234 912; fax: +420 532 234 996.
E-mail addresses: petra.hanakova@fnbrno.cz, hanakopet@seznam.cz
(P. Hana´kova´).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.12.003(TLE). Wiebe et al.6 published a randomized controlled study of
surgery in TLE and endorsed surgery as a superior to prolonged
treatment with antiepileptic drugs (AED). At one year after surgery,
a statistically signiﬁcant difference was conﬁrmed between
patients who underwent surgery and medically treated patients.
Engel et al.7 recently published the results of an Early Randomized
Surgical Epilepsy Trial (ERSET) study of TLE patients after two
failed AED treatments. Among patients with newly intractable
disabling mesial TLE, resective surgery plus AED treatment
resulted in a lower probability of seizures at the 2-year follow-
up visit than continued AED treatment alone.
There has not been a similar controlled study focused on
extratemporal epilepsy (exTLE).
Literature data report a wide range of seizure freedom in
exTLE patients, varying from 25% to 80%,2,3,8–16 Some predictive
factors are believed to play roles in postsurgical outcome.vier Ltd. All rights reserved.
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on MRI or conﬁrmed histologically. Several studies reported
worse postoperative seizure reduction if a lesion was not found
preoperatively on MRI.2,9,16,17
We evaluated 77 patients with refractory exTLE who under-
went surgery in Epilepsy Center Brno. Our purpose was to evaluate
seizure outcome following epilepsy surgery and to assess the
impact of preoperative MRI, histopathological ﬁndings, number of
preoperatively used antiepileptic drugs (AEDs), and other predic-
tive factors.
2. Methods
We retrospectively analyzed all of the patients with refractory
extratemporal epilepsy (exTLE) who had undergone resective
surgery in St. Anne’s University Hospital in Brno (Czech Republic)
between August 1995 and January 2010 and who had reached at
least 1 year outcome after the surgery. We identiﬁed 77 patients.
Of those 77, 4 were excluded from the analysis because of lost
outcome due to the death of the patients. The causes of death
were: sudden unexplained death in epilepsy (SUDEP), drowning,
heart attack, and trafﬁc accident (each in one patient). We thus
studied 73 patients with exTLE who achieved outcome longer
than 1 year. We analyzed 40 patients who reached at least the 5-
year follow-up visit in more detail. The patients’ demographic
data were obtained from medical charts. All patients underwent
a complete preoperative evaluation to assess the extent of
resection.
2.1. Video-EEG evaluation
Scalp video-EEG was recorded with the international 10–20
system with additional electrodes (anterotemporal T1, T2 and
supraorbital SO1, SO2). The scalp recording was performed on the
64-channel Brain Quick system (Micromed) or the 64-channel
Alien Deymed system.
Of the 73 patients, 38 (52.1%) underwent invasive EEG.
Intracranial recordings with inserted depth electrodes alone were
performed in 25 patients; depth electrodes in combination with
subdural electrodes (strip or grid) were used in 6 patients; 4
patients were examined with subdural electrodes only. The
invasive EEG had to be repeated in 3 cases. Intracerebral 5-, 10-,
and 15-contact platinum semiﬂexible Microdeep electrodes DIXI
or ALCIS (with an electrode diameter of 0.8 mm, a contact length of
2 mm, and a 1.5 mm distance between contacts) and 6- or 8-
contact platinum subdural strips electrodes (Radionics) or 32-
contact platinum subdural grids (Radionics) were used. The
invasive video-EEG recording was performed with the 64-channel
Brain Quick system (Micromed), and the 128-channel Alien
Deymed system was used for intracranial video-EEG recording.
Monopolar recordings (a reference electrode on the processus
mastoideus) and special bipolar montages were used to evaluate
the EEG activity. EEG was ampliﬁed with a bandwidth of 0.4–
100 Hz at a sampling rate of 128 Hz.
2.2. Other preoperative evaluation
MRI scans were obtained using the Siemens 1.5 Tesla MRI
scanner. We performed the following sequences in all patients:
T1-weighted axial and coronal sections with and without contrast,
T2-weighted, FLAIR-weighted, and TIR axial and coronal sections of
the whole brain. MRI did not reveal a lesion in 24 (32.9%) of
patients. Fluorodeoxyglucose positron emission tomography
(FDG-PET) was performed in the interictal state on a Siemens
tomography scanner. A complete neuropsychological evaluation
was conducted on all patients. As needed, 24 of the 73 patients(32.9%) underwent interictal and ictal single-photon emission
computed tomography (SPECT) to obtain the subtraction of ictal
SPECT coregistred on MRI (SISCOM).
2.3. Histopathological evaluation
Evaluable formalin-ﬁxed parafﬁn-embedded tissues of extra-
temporal lobe resection specimens were available from all
patients. All the parafﬁn-embedded tissue specimens, slides, and
histopathology reports were retrieved from the ﬁles of the First
Department of Pathological Anatomy of St. Anne’s University
Hospital and examined by a histopathologist. All examined
resected tissues were identically treated, ﬁxed in a 10% neutral
buffered formalin, grossly inspected, measured, and cut so as to
obtain representative tissue slices perpendicular to the cortical
surface. Representative tissue slices were routinely processed and
parafﬁn embedded. 5 mm thick tissue sections were stained by
hematoxylin and eosin, evaluated under light microscope, and
reported.
2.4. Surgery procedure
All procedures were performed in the Epilepsy Center Brno.
The type and extent of the surgery was chosen individually on the
basis of the preoperative evaluation. The surgical procedures
included lesionectomy with resection of adjacent epileptogenic
cortex, isolated lesionectomy, and corticectomy on the basis of
invasive EEG, which was also performed with neocortical
stimulation when the epileptogenic zone was located near the
eloquent cortex. One patient underwent lobectomy and one had
an extended extratemporal lesionectomy with amygdalohippo-
campectomy. Three patients underwent re-operation. The out-
come after the re-operation was included in the study in these
patients.
Preoperative electrocorticography was performed in 59
patients; 29 patients underwent fMRI; 2 patients had awake
craniotomy when the lesion was located close to or involving the
eloquent cortex.
2.5. Evaluation of surgical outcome
Surgical outcome was annually assessed using Engel’s modiﬁed
classiﬁcation for 5 years after surgery and at the latest follow-up
visit.18 All patients were seen regularly (at least once per year) in
the outpatient clinic and had results from at least 2 medical follow-
up visits (after 1 year and at the last follow-up visit). The seizure
outcome was evaluated at a given point in time (at the follow-up
visit) and the time-point actually reﬂects the situation of the
preceding entire year as well.
2.6. Statistical analysis
Statistical analysis was performed using SPSS Statistics 18.
Continuous variables were summarized using standard descriptive
statistics (mean and standard deviation). The statistically signiﬁ-
cant difference between epilepsy duration, the age at epilepsy
onset, the age at the time of epilepsy surgery, and surgical efﬁcacy
was determined using the analysis of variance (ANOVA). A chi-
square test was used to evaluate the association between
histological etiology and outcomes. The chi-square test was also
used to evaluate the association between preoperative MRI-
detected lesions and postsurgical outcome. A p value was
considered as statistically signiﬁcant if p < 0.05.
We present the seizure outcomes of the 40 patients who
reached the 5-year follow-up visit using Kaplan–Meier survival
analysis.
Fig. 1. Localization of the seizure onset zone in all patients (F – frontal lobe epilepsy;
CRE – central region epilepsy; OINZ – operculo-insular epilepsy; O – occipital lobe
epilepsy; TPO – seizures arising from temporal-parietal-occipital boundary; Other –
multilobar seizure onset) (displayed in number of patients; percentages).
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3.1. Patient demographics
We analyzed 73 patients (46 men and 27 women) aged from 1
to 51 years with an average of 28.3  11.4 years (a median age of 27
years). The average epilepsy duration was 14.0  10.6 years (ranged
from 0.5 to 45 years). The average age at the time of epilepsy surgery
was 28.3  11.4 years (ranged from 1 to 51 years) and the average
age at epilepsy onset was 14.2  10.9 years (ranged from 0 to
48 years). At the time of surgery, 7 of the 73 patients (9.6%) were
younger than 16 years.
3.2. Seizure onset zone
Based on a preoperative investigation, we assessed the probable
seizure onset zone (SOZ) in all patients. The SOZ was localized on
the right side in 44 patients and on the left side in 29. The most
frequent SOZ location was the frontal lobe (in 29 of the 73 patients;
39.7%). Other SOZ locations are shown in Fig. 1.
3.3. Seizure outcome
All 73 patients reached the 1-year follow-up visit, 69 reached
2 years, 59 reached 3 years, 47 reached 4 years, and 40 reached
5 years. The last follow-up visit in all patients ranged from 1 to
15 years with an average of 6.15  3.84 years.
At the 1-year follow-up visit, 38 of the 73 patients (52.1%)
were classiﬁed as Engel I, 7 (9.6%) as Engel II, 16 (21.9%) as Engel
III, and 12 (16.4%) as Engel IV. At the 5-year follow-up visit, 22
out of 40 patients (55.0%) were classiﬁed as Engel I, 6 (15.0%) as
Engel II, 5 (12.5%) as Engel III, and 7 (17.5%) as Engel IV. At the
last follow-up visit, 37 of the 73 patients (50.7%) were classiﬁed
as Engel I, 11 (15.1%) as Engel II, 10 (13.7%) as Engel III, and
15 (20.5%) as Engel IV.
Forty patients reached at least the 5-year follow-up visit, and
the last follow-up visit for these 40 patients ranged from the 5-year
visit to the 15-year visit, with an average of 9.23  2.82 years. Engel
IA outcome was reached in 21 out of the 40 patients (52.5%) by the 1,
2, and 3-year follow-up visits, in 20 (50%) by the 4-year follow-up
visit, and in 19 (47.5%) by the 5-year follow-up visit. At the last follow-
up visit (average 9.23 years after the surgery), 15 of these 40 patientsFig. 2. Seizure outcome of the 40 patients who reached at least the 5-year follow-up vis
X-axis in years.(37.5%) were classiﬁed in the same category every year. We present
the seizure outcomes of the 40 patients who reached at least the 5-
year follow-up visit in a Kaplan–Meier survival curve (Fig. 2).
3.4. Histopathology
Histopathological ﬁndings are shown in Fig. 3. The most
frequent ﬁndings were low grade gliomas, and developmental glio-
neural tumors [dysembryoplastic neuroepithelial tumor (DNET)
and ganglioglioma] and malformations of cortical development
(MCD) (each in 21 patients – 28.8%). In 7 of the 73 (9.6%), the
histopathology was negative or inconclusive (all with preopera-
tively normal MRI). Four patients were classiﬁed as focal cortical
dysplasia type IIIb according to ILAE classiﬁcation (i.e. combination
of ganglioglioma and FCD). The most frequent ﬁndings within the
‘‘tumoral group’’ were group with diagnosed oligodendroglioma
(grade II) (in 6 out of 21 patients) and ganglioglioma (grade I) (in 5
out of 21 patients) and DNET (in 4 out of 21 patients) (see Fig. 3).it in a Kaplan–Meier survival curve (displayed in number of patients; percentages).
Fig. 3. Histopathological ﬁndings in the whole group of 73 patients (displayed in numbers of patients; percentages).
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We observed 2 complications associated with invasive EEG
monitoring (out of 38 procedures – 5.2%). We observed an
asymptomatic hematoma following the depth electrode insertion
in 1 patient and an edema following the grid placement in 1
patient. Both complications resolved without consequence with-
out the need for surgical intervention.
Following the epilepsy surgery, we observed surgery-related
complications in 3 of the 73 patients (4.1%): a hematoma in the
post-resection cavity in 1 patient and extracerebral bleeding into
the subdural and/or epidural space in 2 patients. All 3 patients had
revision of the bleeding and we did not observe any long-term
consequences of these complications.
Another 7 of the 73 patients (9.6%) had permanent
neurological deﬁcits following the surgery: paresis of the upper
limb in 3 patients and hemiparesis in 1 patient following
resection in the peri-central or parietal regions (in all classiﬁed
as mild); 3 other patients had visual ﬁeld deﬁcits (quadran-
topsia) after resection in either the parietal or occipital lobes. All
of these complications were to be expected due to the surgery
localization.
3.6. Antiepileptic drug treatment following the surgery
The number of AEDs used in the past history of the patients at
the time of the surgery varied from 2 to 14 with an average of
6.8  3.2. The policy in our center is to start to discontinue AEDs after
successful surgery based on individual decisions for each patient.
At the 5-year follow-up visit, 10 of the 40 patients (25.0%) were
completely off AEDs (Fig. 4A). At the 5-year follow-up visit, among
the 19 patients classiﬁed as Engel IA, AED treatment was
completely withdrawn in 10 patients (52.6%) and partially
withdrawn in 26.3% (Fig. 4B).
At the last follow-up visit in all patients, 10 of the 73 patients
(13.7%) were completely off AEDs, in 12 patients (16.4%) the
AEDs had been partially withdrawn (at least one AED from the
combination), and in 14 patients (19.2%) the AEDs remained
unchanged. In the remaining 37 patients (50.7%), the AED
treatment was changed after the surgery. At the last follow-up,
among the 32 patients classiﬁed as Engel IA, AED treatment was
completely withdrawn in 31.3% and partially withdrawn in
34.4%.3.7. Predictors of postsurgical outcome
No statistically signiﬁcant difference between epilepsy dura-
tion, the age at epilepsy onset, the age at the time of epilepsy
surgery, and surgical efﬁcacy was established by ANOVA
(p = 0.481, 0.45, and 0.512, respectively).
Preoperatively, 49 (67.1%) patients had abnormal MRI ﬁndings.
Of these 49 patients, 30 (61.2%) were classiﬁed as Engel I at the last
follow-up visit, 7 (14.3%) as Engel II, 4 as Engel III (8.2%), and 8
(16.3%) as Engel IV. Preoperatively, 24 (32.9%) patients had normal
MRI ﬁndings. Of these 24 patients, 7 (29.2%) were classiﬁed as
Engel I at the last follow-up visit, 4 (16.7%) as Engel II, 6 (25.0%) as
Engel III, and 7 (29.2%) as Engel IV. The difference in Engel I
outcome at the last follow-up visit between these two groups was
statistically signiﬁcant [x2 (1) = 6.62; p < 0.01] (Fig. 5).
Of those 24 patients with normal MRI, 13 had FCD diagnosed
histopathologically (5 patients type IA, 4 IB, 4 IIB), 7 specimens
were negative or inconclusive, in 3 patients gliosis was conﬁrmed,
and in 1 ganglioglioma of grade I.
Of the 21 patients with low-grade gliomas and developmental
glio-neural tumors, 16 (76.2%) had Engel class I outcome at the last
follow-up visit (Fig. 6); in the 52 patients with other histopatho-
logical ﬁnding (Fig. 3) 21 (40.4%) were classiﬁed as Engel I at the
last follow-up visit. This difference was statistically signiﬁcant
[x2(2) = 6.67; p = 0.035].
The patients with low-grade gliomas and developmental glio-
neural tumors had better outcomes (Engel class IA in 66.7%) than
the patients diagnosed with cortical dysplasia (Engel class IA in
28.6%). This difference was statistically signiﬁcant [x2(2) = 6.69;
p < 0.01].
4. Discussion
We revealed a relatively stable postoperative outcome. At the 1-
year follow-up visit in all patients, 52.1% of patients were classiﬁed
as Engel I; 5 years after surgery, 55.0% were classiﬁed as Engel I; at
the last follow-up visit (mean 6.15 years after surgery), 50.7% were
classiﬁed as Engel I. Literature data report a wide range of seizure
freedom, varying from 25% to 80% of patients with exTLE.2,3,8–16
Some studies analyzed the results of either resective surgery or
other ‘‘palliative’’ procedures like corpus callosotomy and multiple
subpial transsections.19,20 Other studies provided an analysis of
‘‘neocortical’’ epilepsies, combining the results of TLE and exTLE
patients.21 Comparisons of studies in patients with exTLE are
Fig. 4. (A) Antiepileptic medication at the 5-year follow-up visit for the group of 40 patients who reached this follow-up (displayed in number of patients; percentages). (B)
Antiepileptic medication for patients classiﬁed as Engel IA at the 5-year follow-up visit (displayed in number of patients; percentages).
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noticed in the data pooled by Te´llez-Zenteno et al.4 They reported
long-term seizure freedom in 34% of patients in grouped
extratemporal resections, of which 27% were with frontal lobe
resections and 46% with both parietal and occipital lobe resections.
McIntosh et al.11 studied 81 patients with exTLE; the study
showed that the probability of complete seizure freedom at 5 years
postoperative is 15%. This type of measure might be misleading
because it is not usual to use it in these types of studies. On the
other hand, this measurement reﬂects the proportion of patients
whose outcome is really excellent from a long-term point of view.In our study, 37.5% of the patients were completely seizure free at
the 5-year follow-up visit (i.e. classiﬁed as Engel IA at each follow-
up). This number is more than twice that of the McIntosh study.
The better outcome in our study might be explained by the higher
number of patients with benign tumors or DNET and the lower
number of patients with focal cortical dysplasia (FCD) in
comparison to the McIntosh study. Patients with FCD (both types
I and II) were more than 50% of the patients in the McIntosh study,
but less than 30% in our study. This difference emphasizes the large
diversity of surgical series of exTLE patients published in the
literature.
Fig. 5. Postsurgical outcome at the last follow-up visit; difference between patients with ‘‘lesional’’ and ‘‘nonlesional’’ preoperative MRI (displayed in number of patients;
percentages). *p < 0.01.
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(the differences in Engel I outcome gathered at 1-year, 5-year, and
last follow-up visits were insigniﬁcant). Elsharkawy et al.22
reported similar results in 218 patients with exTLE patients. Jeha
et al.2 observed decreased surgical efﬁcacy over time in 70 patients
with frontal lobe epilepsy. While 56% of those patients were
seizure free at the 1-year follow-up visit, only 30% were seizure
free after 5 years.Fig. 6. Postsurgical outcome at the last follow-up visit; difference between patients with
development (displayed in number of patients; percentages). *p < 0.01.Postsurgical outcome is signiﬁcantly affected by many factors,
the most important of which are the ﬁnding of a lesion on
preoperative MRI and ‘‘positive’’ histopathological ﬁndings. Te´llez-
Zenteno et al.16 evaluated the predictive factors for better
postsurgical outcome in more detail in a meta-analysis of 40
studies, of which 13 were performed on patients with exTLE. In
these groups, the odds of being seizure free at least one year after
surgery are two to three times higher in patients with a benign neoplasm + developmental glio-neural tumors and malformation of cortical
P. Hana´kova´ et al. / Seizure 23 (2014) 266–273272preoperative MRI-detected lesion or conﬁrmed histopathological
ﬁndings than in those with no MRI-detected lesion and negative
histopathological ﬁndings. The proportion of seizure-free patients
was 35% in nonlesional epilepsy and 60% in lesional epilepsy.
We conﬁrmed a statistically signiﬁcant association between a
preoperative MRI-detected lesion and the postoperative outcome.
Other studies have shown a worse postoperative seizure reduction
if no lesion was found preoperatively on MRI.2,17,22–25 On the other
hand, Ansari et al.8 found no signiﬁcant association between MRI-
detected lesion and good outcome. These results are poorly
comparable to ours because of differing interpretations of
‘‘lesional’’ and ‘‘nonlesional’’ epilepsy. Ansari et al. classiﬁed
tumors, vascular malformations, and tuberous sclerosis as
‘‘lesional’’ epilepsy and did not include these abnormal ﬁndings
in their study. All other pathologies, such as malformations of
cortical development including cortical dysplasia, polymicrogyria,
ulegyria, gliosis, and chronic inﬂammation, were classiﬁed as a
‘‘nonlesional’’ epilepsy, although some (for example cortical
dysplasia) can be visible as an MRI-detected lesion. The authors
divided the patients classiﬁed with ‘‘nonlesional’’ epilepsy in two
groups: those with a visible MRI-detected lesion and those with a
normal MRI. We classiﬁed all of the patients with visible MRI-
detected lesions as having ‘‘lesional’’ epilepsy (including cortical
dysplasia with a positive ﬁnding on MRI). In the study by Ansari
et al.,8 the most frequent abnormal ﬁnding seen was cortical
dysplasia, which can be more extended and diffused than a visible
MRI-detected lesion, particularly in younger patients3,26 and
hence, could have worse postoperative outcome.
One of the possible reasons for higher efﬁcacy of surgery in
lesional epilepsy could be the easier surgical performance and
complete resection of the epileptogenic zone. This might result in a
better outcome in patients with benign tumors, because patho-
logical neoplastic tissue is more visible and easily distinguishable
from the normal tissue during surgery.27
In our study, benign neoplasms, developmental glio-neural
tumors and malformations of cortical development were histolog-
ically diagnosed as the most frequent pathological ﬁndings.
Boesebeck et al.27 reported a similar distribution of tumors and
malformations in a group of 81 patients as compared to our study.
We found better outcomes at the last follow-up visit in patients
with benign neoplasms + developmental glio-neural tumors than
in patients with cortical dysplasia. In agreement with our study,
tumorous etiology has shown a more favorable seizure outcome in
extratemporal epilepsies.27,28 This association is also supported by
the results of two studies that reported from 80% to 82% of patients
to be seizure free after tumor resection reported worse surgical
outcomes when cortical dysgenesis was conﬁrmed in a tissue
specimen.5,29,30 Other authors reported that a malformation of
cortical development may be poor congruence with electrographic
and with structural and functional radiological ﬁndings.17,31,32
In our study, 52.1% of patients underwent invasive EEG (depth
or subdural electrodes alone or in combination at the same time).
The frequency of use of invasive EEG is reported in a wide range.
McIntosh et al.11 used intracranial electrodes in 26 out of 81
patients (32.1%). Subdural grids and epidural or depth electrodes
were used more frequently (66 out of 81 patients, 81.5%) in a
retrospectively study by Boesebeck et al.27 in which patients had
MRI-detected lesions deﬁned histologically as tumors, vascular
lesions, and cortical gliosis. Jeha et al.2 published the results of 70
patients with frontal lobe epilepsy. Of those 70, 47 (67.1%)
underwent invasive EEG. The different results mostly depend on
the strategy of each center, on the availability of neuroimaging
methods during the presurgical evaluation, and on the placement
strategy of either depth or subdural electrodes.
In 9.6% of patients, we noticed permanent neurological
deﬁcits (mild paresis following the resection in the peri-centralor parietal regions and visual ﬁeld deﬁcits after resection in the
posterior quadrant). All of these complications are to be expected
due to the location of the surgery and all of the patients accepted
these deﬁcits prior to the surgery. The complications are more
frequent in extratemporal than in temporal localization because
of the eloquent cortex in this area and the need for a large
resection to achieve a better postsurgical outcome.33 The
spectrum of complications in other studies is very similar to
our ﬁndings. The number is generally low. Elsharkawy et al.22
observed outcomes and complications in 218 patients with
extratemporal refractory epilepsy who had surgery between
1991 and 2005. Overall, 4.6% had permanent and 5.0% had
transient neurological deﬁcits. The most frequent were paresis,
visual ﬁeld defects, and facial palsy. Mulholland et al.12 reported
a relatively high percentage of complications. They observed
postoperative complications (namely meningitis, brain abscess,
and wound infection) in 3 patients (17.6%). But the whole group
contained only 17 patients. They recorded minor complications
in 4 patients, including blurring of vision, trembling in the arm,
and cephalohematoma. It is challenging to compare complica-
tions with other studies because of non-uniform classiﬁcation
systems.
In our study, the number of AEDs used in the past history of the
patients at the time of surgery varied from 2 to 14 with an average
of 6.8. In a study by Mulholland et al.,12 a similar average of 6.5
AEDs per patient was used. At the last follow-up visit, among 32
patients classiﬁed as Engel IA, AED treatment had been withdrawn
completely in 31.3%. The previously published results of similar
studies are conﬂicting. Kerling et al.34 published a prospective pilot
study of AED withdrawal in 34 out of 60 patients who underwent
surgery. He compared this group with 26 patients without
discontinuation of AEDs. All of the patients with extratemporal
epilepsy (6 out of 34) were in the withdrawal group. The
association with a higher risk of seizure recurrence was conﬁrmed
(38.5% in the group with unchanged medication as compared to
23.6% in the withdrawal group). In contrast, Schiller et al.,35
reported a higher risk of seizure recurrence after discontinuation of
AEDs (7% of patients with unchanged medication versus 36% in
withdrawal group).
In our study, we did not conﬁrm a statistically signiﬁcant
difference between epilepsy duration and surgical efﬁcacy. We did
not ﬁnd a difference in epilepsy duration between patients with
lesional (14.0 years) and nonlesional (14.3 years) epilepsy, either.
However, epilepsy duration is still a discussed predictive factor.24
In our patients, the time from seizure onset to surgery was similar
to that in the study by Elsharkawy et al.36 who reported 17.8  10.0
years. There are inconsistencies among the published results. Our
conclusion is in line with studies by Jeha et al.,2 Ansari et al.,8
McIntosh et al.11 and Boesebeck et al.27 In contrast, Kral et al.24 found
an association between epilepsy duration and postoperative out-
come, but that study observed only patients with FCD. Teutonico
et al.,37 conﬁrmed a statistically signiﬁcant association in 120
children under 16 years of age. Therefore in our results, we have
to consider different histological etiology as well as the wide range of
patient ages. Elsharkawy et al.22 described a signiﬁcant association
between epilepsy duration and outcome by univariate analysis, but
this was not conﬁrmed by multivariate analysis. The theory that
epilepsy duration affects outcome through other factors is supported
by these results.
5. Conclusions
In conclusion, our results showed that surgery for patients with
exTLE is an effective procedure with relatively stable efﬁcacy over
time. The number of patients included in the study did not allow us
to analyze the efﬁcacy of the surgery in patients with different SOZ
P. Hana´kova´ et al. / Seizure 23 (2014) 266–273 273localizations. Such a detailed analysis would lead to a relatively
smaller number of patients. Because of the controversies and
diversities within the literature data concerning this issue, a
prospective controlled trial in the future will be necessary to
conﬁrm the results obtained from retrospective analyses. The
presence of preoperative MRI-detected lesions and the histopath-
ological ﬁnding of low-grade tumors (and including developmen-
tal glio-neural tumors) seem to be the two most important factors
inﬂuencing the favorable prognosis for patients with extratem-
poral epilepsy. The relatively higher incidence of permanent
neurological deﬁcit postoperatively both in our study and in other
studies is undoubtedly caused by the necessity of performing the
surgery near the eloquent regions (sensory-motor region, visual
cortex, etc.).
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